Locations:
Search
Reconsidering axillary lymph node dissection as well as depth of surgical margins
Pediatric specialists unpack new evidence, considerations for care and what’s ahead
Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors
A multi-pronged strategy for tackling cancer access problems
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Early results show patients experiencing deep and complete response
Inclusion of genomic profiling and risk factors recommended for treatment planning
Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer
Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin
Treatment assigned FDA review date in June 2025
Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit
Advertisement
Advertisement